<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1725">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04330144</url>
  </required_header>
  <id_info>
    <org_study_id>3-2020-0036</org_study_id>
    <nct_id>NCT04330144</nct_id>
  </id_info>
  <brief_title>Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)</brief_title>
  <official_title>A Study of Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gangnam Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gangnam Severance Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is no known definite treatment after exposure to SARS-CoV-2, but the some animal and
      clinical trials confirmed the efficacy of hydroxychloroquine (HCQ) or chloroquine against
      SARS-CoV-2. Thus, in this study, we aim to evaluate the efficacy and safety of
      hydroxychloroquine as post exposure prophylaxis for SARS-CoV-2.

        -  Primary end point: comparison the rate of COVID-19 between PEP with HCQ and control
           group.

        -  Secondary end point: Comparison of the rate of COVID-19 according to the contact level
           (time, place, degree of wearing personal protective equipment).

        -  Safety comparison: Safety verification by identifying major side effects in the HCQ
           group.&quot;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2020</start_date>
  <completion_date type="Anticipated">March 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of COVID-19</measure>
    <time_frame>PCR test of COVID-19 at 14 days after the contact from confirmed case</time_frame>
    <description>After postexposure prophylaxis, the rate of COVID-19 conversion between two groups</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2486</enrollment>
  <condition>Contact Person From COVID-19 Confirmed Patient</condition>
  <arm_group>
    <arm_group_label>administration of hydroxychloroquine as PEP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>control with no PEP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine as post exposure prophylaxis</intervention_name>
    <description>1day: Hydroxychloroquine 800mg Qd po 2-5dy: Hydroxychloroquine 400mg Qd po</description>
    <arm_group_label>administration of hydroxychloroquine as PEP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Others(No intervention)</intervention_name>
    <description>No treatment. Close monitoring and quarantine.</description>
    <arm_group_label>control with no PEP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A contact person from confirmed case of SARS-CoV-2 infection

          -  Medical staff exposed from confirmed case of SARS-CoV-2 infection in hospitals

          -  Persons exposed to SARS-CoV-2 in COVID-19 outbreak situation with certain workplaces,
             religious groups, and military, etc.

               -  Subjects of study include both symptomatic and asymptomatic contacts.

        Exclusion Criteria:

          -  Hypersensitivity to Chloroquine or Hydroxychloroquine

          -  Those who are contraindicated in Hydroxychloroquine administration according to the
             permission requirements such as pregnant women, nursing mothers, visual disorders,
             macular disease, and porphyria, etc.

          -  Human immunodeficiency virus (HIV) infected person

          -  Patients with autoimmune disease (Systemic lupus erythematosus, Mixed connective
             tissue disease)

          -  Patients with autoimmune rheumatoid inflammatory disease (AIIRD; Autoimmune
             inflammatory rheumatic diseases - Ankylosing spondylitis, Rheumatic arthritis,
             Psoriatic arthritis)

          -  Arrhythmia, liver cirrhosis of Child Pugh C, chronic renal failure with eGFRâ‰¤30mL /
             min / 1.73m2

          -  A person who is positive in the COVID-19 screening PCR test before starting PEP
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong Goo Song, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gangnam Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yong Goo Song, Professor</last_name>
    <phone>82-2-2019-3310</phone>
    <phone_ext>3310</phone_ext>
    <email>imfell@yuhs.ac</email>
  </overall_contact>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 30, 2020</study_first_submitted>
  <study_first_submitted_qc>March 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2020</study_first_posted>
  <last_update_submitted>March 31, 2020</last_update_submitted>
  <last_update_submitted_qc>March 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gangnam Severance Hospital</investigator_affiliation>
    <investigator_full_name>Young Goo Song</investigator_full_name>
    <investigator_title>Professor, Department of Internal Medicine,</investigator_title>
  </responsible_party>
  <keyword>Postexposure prophylaxis</keyword>
  <keyword>hydroxychloroquine</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>COVID-19</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

